Clinical drug development expert brings 35 years of experience to SciMar’s mission to accelerate life-changing drugs to market
ALLENTOWN, NJ, July 14, 2023 – SciMar ONE, Inc. (SciMar) welcomes Marco Taglietti, MD, to its Board of Advisors.
Marco is a 35-year pharmaceutical industry veteran whose career spans various clinical and executive roles with Fortune 500 and independent pharmaceutical companies. An expert drug developer and business builder, Marco will advise SciMar’s growth strategy for its AI-powered drug development technology, The DV Platform™.
Marco’s passion for improving patient outcomes by developing therapies with high impact helped him gain regulatory approval of over 35 products through clinical research programs to commercialization. In his last role, Marco was the Chief Executive Officer of SCYNEXIS, Inc. and successfully restructured the organization via a series of strategic initiatives that raised over $450M and led the company to the launch of ibrexafungerp (BREXAFEMME) in the U.S. in 2021.
“I am pleased to partner with SciMar to advance an innovative approach that removes the slow and tedious inefficiencies associated with strategic drug development,” said Marco. “SciMar applies AI-based technology across requisite methods that successfully move drugs towards commercialization while integrating volumes of evidence-based data points to accelerate pharma’s status quo.”
When asked about the timing of SciMar’s technology, Marco replied, “We live in an era where big pharma needs to get serious about eliminating entrenched inefficiencies in drug development, both for their own financial health as well as for the health of the patients they seek to serve.”
“Besides being a pleasure to work with, Marco brings a holistic view of drug development to SciMar. His perspectives provide a unique combination of clinical knowledge to meet patient needs plus the business acumen to build a sustainable business. Together this knowledge has allowed him to successfully develop 35 different drugs over his career and will now make him an invaluable advisor,” said Donna Conroy, MS, SciMar co-founder and CEO. “As the industry looks for solutions that close the growing financial chasm associated with patent expiry and increasing development costs, I will look to Marco often for his guidance and perspective as we deploy the DV Platform across the industry while building SciMar ONE, Inc.”
Marco earned a medical degree from the University of Pavia, Italy, and is board certified in both infectious diseases and dermatology.
About SciMar ONE, Inc.:
SciMar ONE, Inc. is a New Jersey-based technology company using AI to enable the pharmaceutical industry to accelerate drug development. SciMar’s proprietary AI SaaS technology, the DV Platform™, accelerates life-changing drugs to market with data integration and workflow automation tools that remove inefficiencies within strategic drug development. Learn more at: scimarone.com.
Media Contact:
SciMar ONE, Public Relations